Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 27Non-metastatic Castration-resistant Prostate Cancer 2Neoplasm Metastasis 2Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Prostate Cancer Metastatic 1Non-metastatic Prostate Cancer 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms by Site 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Low Risk Prostate Cancer 1Genital Neoplasms, Male 1Genital Diseases, Male 1Castration Levels of Testosterone 1Advanced Prostate Carcinoma 1

Interventions

padeliporfin 4sipuleucel-T 1rucaparib 1niraparib 1luprolide acetate gel depot 1apalutamide 1Therapeutics 1Radiotherapy 1Radiation Dose Hypofractionation 1Paclitaxel 1Leuprolide 1Imatinib Mesylate 1Gemcitabine 1Cisplatin 1Chemical Fractionation 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Genital Neoplasms, Male × apalutamide × Clear all
NCT02578797 2023-11-09

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Aragon Pharmaceuticals, Inc.

Phase 1 Completed
45 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡